Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Sessile serrated adenomas may have low risk of malignant progression in young patients

12 Apr 2018

Sessile serrated adenomas (SSAs) appear to have a prolonged dwell time and are unlikely to develop into cancer, especially in young patients, a study suggests.

Researchers examined two separate cohorts consisting of a consecutive series of patients who underwent outpatient colonoscopy (polyp cohort; mean age 58 years; 50.6 percent female) and a consecutive series of patients who contributed resection specimens for colorectal carcinoma (CRC; cancer cohort; mean age 69 years; 46.8 percent female).

SSA prevalence by age was compared against the ages of patients with BRAF-mutated CRC. Results showed that the prevalence of SSAs in the polyp cohort was 20.1 percent, and the rate was similar across age groups. On the other hand, BRAF-mutated CRCs in the cancer cohort were very rare (3.8 percent) in patients aged <50 years and uncommon (9.3 percent) in those aged <60 years, but increased to 39.8 percent in older patients (age >80 years).

The present data demonstrate a high prevalence of SSAs in young patients, but a distinct lack of BRAF-mutated carcinomas in patients aged <60 years, suggesting that the risk of malignant progression for sporadic SSAs in young patients is low, researchers said.

However, researchers warned that young patients with serrated polyposis syndrome are of course at a greater risk of developing CRC and require very close surveillance. Patients with multiple SSAs but who do not meet the criteria for serrated polyposis syndrome should also be followed closely as polyp counts are usually considered to be cumulative over time.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.